[In vitro antifungal resistance in Candida albicans from HIV-infected patients with and without oral candidosis.].

The main purpose of this study has been to determine the in vitro antifungal susceptibility of clinical isolates from HIV-infected or AIDS patients, depending on the presence of oral candidosis. The oral cavity of 307 HIV-infected or AIDS patients was examined and an oral swab was cultured on Sabouraud glucose agar and studied by conventional mycological methods. In vitro antifungal susceptibility to amphotericin B, nystatin, fluconazole, itraconazole and ketoconazole was tested by disk diffusion with Neo-Sensitabs tablets (Rosco Diagnostica, Dinamarca). One hundred and thirty five Candida albicans isolates (91 serotype A, 38 serotype B, three C. albicans variety stellatoidea and three untyped isolates), three Candida krusei and two Candida glabrata were obtained. All the isolates were susceptible to nystatin and amphotericin B. However, 7.9% isolates were resistant to fluconazole and 2.9% isolates were resistant to ketoconazole or itraconazole. Nearly all C. krusei and C. glabrata isolates, 31% patients with candidosis and 20% Candida-colonized patients showed decreased susceptibility to azoles. This study shows that polyenes had a great in vitro efficacy against clinical isolates from HIV-infected patients and that in vitro resistance to azoles is not as high as observed in other countries.

[1]  S. Masetto the progression of , 2022 .

[2]  G. Quindós,et al.  Multicenter evaluation of Neo-Sensitabs, a standardized diffusion method for yeast susceptibility testing. , 1999, Revista iberoamericana de micologia.

[3]  B. Gazzard,et al.  Non-albicans oral candidosis in HIV-positive patients. , 1999, The Journal of antimicrobial chemotherapy.

[4]  J. Gallant,et al.  Infection due to fluconazole-resistant Candida in patients with AIDS: prevalence and microbiology. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  B. Posteraro,et al.  Analysis of the risk factors associated with the emergence of azole resistant oral candidosis in the course of HIV infection. , 1996, The Journal of antimicrobial chemotherapy.

[6]  S. Redding,et al.  Detection and significance of fluconazole resistance in oropharyngeal candidiasis in human immunodeficiency virus-infected patients. , 1996, The Journal of infectious diseases.

[7]  J. Emeterio,et al.  Candidiasis de la cavidad oral: etiología, patogenia y diagnóstico de laboratorio , 1996 .

[8]  R. Chaisson,et al.  Risk factors for fluconazole-resistant candidiasis in human immunodeficiency virus-infected patients. , 1996, The Journal of infectious diseases.

[9]  E. Johnson,et al.  Itraconazole susceptibilities of fluconazole susceptible and resistant isolates of five Candida species. , 1995, The Journal of antimicrobial chemotherapy.

[10]  J. Bikandi,et al.  Variability in expression of antigens responsible for serotype specificity in Candida albicans. , 1995, Microbiology.

[11]  J. Still,et al.  A comparison of susceptibility to five antifungal agents of yeast cultures from burn patients. , 1995, Burns : journal of the International Society for Burn Injuries.

[12]  B. Petrini,et al.  Oral Candida albicans isolates with reduced susceptibility to fluconazole in Swedish HIV-infected patients. , 1995, Scandinavian journal of infectious diseases.

[13]  C Scully,et al.  Emergence of azole drug resistance in Candida species from HIV-infected patients receiving prolonged fluconazole therapy for oral candidosis. , 1995, The Journal of antimicrobial chemotherapy.

[14]  M. Mendoza,et al.  Sensibilidad de los serotipos A y B de Candida albicans y otras levaduras del género Candida frente a diferentes azoles , 1994 .

[15]  W. Strull,et al.  Fluconazole-resistant Candida in AIDS patients. Report of two cases. , 1993, Oral surgery, oral medicine, and oral pathology.

[16]  A. Polak,et al.  Susceptibility of yeast isolates from defined German patient groups to 5‐fluorocytosine * , 1992, Mycoses.

[17]  S. Buchbinder,et al.  Progression to AIDS in HIV‐infected homosexual and bisexual men with hairy leukoplakia and oral candidiasis , 1992, AIDS.

[18]  M. Katz,et al.  Oral candidiasis in HIV infection: pseudomembranous and erythematous candidiasis show similar rates of progression to AIDS. , 1991, AIDS.

[19]  S. Shadomy,et al.  Comparative in vitro antifungal susceptibility studies with 30 serotype A and B isolates of Candida albicans. , 1991, Diagnostic microbiology and infectious disease.

[20]  M. Dietrich,et al.  Oral candidosis in HIV‐infected patients. Prognostic value and correlation with immunological parameters , 1990, Mycoses.

[21]  E. Dunbar,et al.  Once-weekly fluconazole to prevent recurrence of oropharyngeal candidiasis in patients with AIDS and AIDS-related complex: a double-blind placebo-controlled study. , 1990, The Journal of infection.

[22]  R. Hay Overview of studies of fluconazole in oropharyngeal candidiasis. , 1990, Reviews of infectious diseases.

[23]  N. Clumeck,et al.  FLUCONAZOLE VERSUS KETOCONAZOLE IN OROPHARYNGEAL CANDIDIASIS IN AIDS , 1989, The Lancet.

[24]  R. Guttu Oral candidiasis in high risk patients as the initial manifestation of the acquired immunodeficiency syndrome , 1984 .

[25]  J. Casals,et al.  Tablet sensitivity testing on pathogenic fungi. , 1979, Journal of clinical pathology.